Ops, QA staff escape Genzyme's ($GENZ) job cuts

Genzyme ($GENZ) last week cut 392 filled and unfilled jobs at several locations, executing the first step in its plan to eliminate 1,000 by the end of next year. Employees got the word on Thursday.

The 1,000 represents about one-twelfth of the Cambridge, MA, biotech's workforce.

Some 185 of those cuts are in Massachusetts, but not at the troubled Allston manufacturing plant. The plant is currently operating under a consent decree with the FDA for remediation of manufacturing shortcomings. The company has been and continues to hire manufacturing and quality assurance employees, says the Boston Globe. Plans call for an additional 500 to 600 such jobs in Allston, Framingham, and elsewhere by the end of next year.

- see the article
- here's the Globe report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.